David Schenkein, CEO, Agios Pharmaceuticals
David Schenkein, the former senior vice president in charge of cancer drug development at Genentech, has been tapped to replace Kevin Starr as CEO. Starr, a partner at Third Rock Ventures, had been interim CEO during the ramping up phase. Agios also announced that Duncan Higgons (photo) will join the company as chief operating officer.
Related Articles:
Cambridge start-up reaps $33M in first round
Latest Commentary